GlassScriptPhysician profile
Surrinder P Dang
NPI 1699755116
$8,435.64
in general payments reported to CMS, 2019-2025
57 companies · $1,031 in 2025
The $1,031 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,406 · 2020: $558 · 2021: $1,017 · 2022: $1,187 · 2023: $1,242 · 2024: $1,995 · 2025: $1,031.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,647 · Grant: $501 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,646.93 |
| Grant | $500.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $120.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $882.10 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $768.69 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Abbvie INC. | $706.24 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $679.15 | 2019-2025 | Piqray, Kisqali |
| Amgen INC. | $550.35 | 2019-2023 | Kyprolis, Blincyto |
| Welch Allyn | $432.31 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $431.08 | 2019-2025 | Opdivo |
| Seagen INC. | $426.76 | 2019-2023 | Tukysa, Adcetris, Padcev |
| Janssen Biotech, INC. | $314.04 | 2019-2025 | Rybrevant, Darzalex, Tecvayli |
| Celgene Corporation | $233.41 | 2020-2025 | Opdualag, Pomalyst, Reblozyl |
| Gilead Sciences, INC. | $229.12 | 2019-2025 | Trodelvy |
| Pharmacyclics LLC, An Abbvie Company | $205.57 | 2019-2023 | Imbruvica |
| Genentech USA, INC. | $177.48 | 2019-2024 | Tecentriq |
| Eisai INC. | $164.82 | 2019-2024 | |
| Genzyme Corporation | $164.25 | 2019-2025 |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $133.57 | 2022-2025 | Ninlaro, Iclusig |
| Astellas Pharma US INC | $128.95 | 2019-2025 | Xtandi |
| Springworks Therapeutics, INC. | $127.72 | 2024-2025 | Ogsiveo |
| Lilly USA, LLC | $116.38 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Astrazeneca Pharmaceuticals LP | $110.48 | 2022-2025 | Imfinzi, Calquence |
| Incyte Corporation | $105.09 | 2023-2025 | Jakafi |
| Glaxosmithkline, LLC. | $95.70 | 2022-2025 | Jemperli, Ojjaara, Zejula |
| Exelixis INC. | $79.91 | 2021-2025 | Cabometyx |
| Boston Scientific Corporation | $77.40 | 2020 | |
| Karyopharm Therapeutics INC. | $69.81 | 2021-2023 | Xpovio |
| Pharmaessentia USA Corporation | $59.76 | 2023-2024 | Besremi |
| Alexion Pharmaceuticals, INC. | $55.70 | 2024 | Ultomiris |
| Array Biopharma INC | $53.20 | 2021-2025 | Braftovi, Mektovi, Tukysa |
| Beigene USA, INC. | $52.81 | 2021-2025 | Tevimbra, Brukinsa |
| Beone Medicines USA, INC. | $52.53 | 2025 | Brukinsa |
| Acrotech Biopharma INC. | $49.98 | 2022-2025 | Beleodaq |
| Kite Pharma, INC. | $47.54 | 2020-2025 | Yescarta |
| Deciphera Pharmaceuticals INC. | $44.48 | 2022-2024 | Qinlock |
| Biocompatibles, INC. | $40.13 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.73 | 2019-2020 | |
| Puma Biotechnology, INC. | $38.84 | 2023 | |
| Immunocore Limited | $36.14 | 2025 | Kimmtrak |
| Janssen Pharmaceuticals, INC | $35.30 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.88 | 2019-2022 | |
| Daiichi Sankyo INC. | $34.32 | 2024-2025 | Enhertu |
| Emd Serono, INC. | $34.07 | 2022-2023 | Tepmetko |
| Regeneron Healthcare Solutions, INC. | $33.63 | 2024-2025 | Lynozyfic, Libtayo |
| Blueprint Medicines Corporation | $33.20 | 2024 | Ayvakit |
| Sun Pharmaceutical Industries INC. | $31.46 | 2023 | Yonsa, Odomzo |
| Aurobindo Pharma USA, INC. | $29.79 | 2019-2020 | |
| Sobi, INC | $25.61 | 2022 | |
| Epizyme, INC. | $22.16 | 2021 | |
| Sumitomo Pharma America, INC. | $20.23 | 2024 | Orgovyx |
| Cti Biopharma Corp. | $20.13 | 2023 | Vonjo |
| Mirati Therapeutics, INC. | $19.21 | 2023 | Krazati |
| Servier Pharmaceuticals LLC | $18.06 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $16.63 | 2019 | |
| Eusa Pharma (US) LLC | $16.46 | 2021 | |
| Fresenius Kabi USA, LLC | $14.85 | 2025 | |
| Adc Therapeutics America, INC. | $14.43 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Surrinder Dang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.